PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

USPTO PatentsView assignee record - 33 granted patents across 9 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Biocytogen ranks #9,447 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 9 technology areas.

#9,447
of 49,997 US assignees by volume
Top 25%
by Innovation Score (44.8/100)
15.5
avg claims per patent

USPTO PatentsView assignee plate

Corpus R9447 · Foreign Corporation #9,447 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-SMALL 33 grants
  • UPPER-Q #9,447/49,997
  • PHOTO-FINISH Beam Engineering…
  • CPC-NARROW C07K · 9 areas
  • INNOV-PAR 44.8/100
  • CLAIMS-RICH 15.5 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Beam Engineering for Advanced Measurements Co. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Biocytogen’s 44.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Biocytogen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Biocytogen's Innovation Score is 44.8/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Biocytogen?

Each dot is one of Biocytogen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biocytogen’s own 15.5 claims/patent is ABOVE the 12.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Biocytogen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 32.933.033.03333.033.033.1 010203040 Granted patents (volume) Avg claims / patent Blue Rhino Global Sourcing, Inc. - 33, 1Blue Rhino Global…Btsr International S.P.A. - 33, 12.7Btsr Internationa…Beam Engineering for Advanced Measurements Co. - 33, 10.33Beam Engineering…BioMedical Enterprises, Inc. - 33, 11.82Biomedical Enterp…Biolase, Inc. - 33, 15.82BiolaseBlaize, Inc. - 33, 17.79BlaizeBlinker Inc. - 33, 28.7BlinkerBluebeam, Inc. - 33, 19BluebeamBiocytogen Pharmaceuticals (Beijing) Co., Ltd. - 33, 15.48Biocytogen Pharma…
Biocytogen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Biocytogen's grants concentrate

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (13 grants) versus a trough of 3 in 2023. By volume, Biocytogen sits between Blue Rhino Global Sourcing, Inc. and Bluebeam, Inc..

Biocytogen's three-year grant acceleration

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. shows 21 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Biocytogen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Biocytogen holds 33 patents at rank #9,452, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Biocytogen

By rank, the assignees closest to #9,452 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Biocytogen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Biocytogen, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Biocytogen ranks #289 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (45 here).

Qnovo Inc. 45 Trimble AB 45 inVia Robotics, Inc. 45 FCI USA LLC 45

Biocytogen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 25% higher than 75% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 20212022202320242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 11 33.3%
2022 13 39.4%
2023 3 9.1%
2024 5 15.2%
2025partial year 1 3.0%

Which technologies does Biocytogen Pharmaceuticals (Beijing) Co., Ltd. patent most?

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s patent record in context - here's where to go next.

  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #9,447 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Biocytogen Pharmaceuticals (Beijing) Co., Ltd. against Blue Rhino Global Sourcing, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 44.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.